newsfilter
← Latest News
GlobeNewswire·

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic engineeringFindings